Company:  KYTHERA BIOPHARMACEUTICAL ... (KYTH)
Form Type:  10-Q
Filing Date:  8/6/2013 
CIK:  0001436304 
Address:  27200 WEST AGOURA ROAD
SUITE 200
 
City, State, Zip:  CALABASAS, California 91301 
Telephone:  818-587-4500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$34.14  
Change: 
-1.64 (-4.58%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$773.51M
Description of Business
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Our objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. Our initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. Our product candidate, ATX-101, is a potential first-in-class, injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Financial Statements
      ITEM 2. Management's Discussion and Analysis of Financial ...
      FINANCIAL STATEMENTS
        CASH FLOW
      ITEM 3. Quantitative and Qualitative Disclosures About ...
      ITEM 4. Controls and Procedures
    PART II. Other Information
      ITEM 1. Legal Proceedings
      ITEM 1A. Risk Factors
      ITEM 2. Unregistered Sales of Equity Securities and Use of ...
      ITEM 6. EXHIBITS
    SIGNATURES
  EXHIBIT 31.1
    Certification of Chief Executive Officer
  EXHIBIT 31.2
    Certification of Chief Financial Officer
  EXHIBIT 32.1
    Certification of Chief Executive Officer and Chief Financial ...
BROKERAGE PARTNERS